Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Geptanolimab + Fruquintinib in mCRC
NCT03977090Phase 1Unknown
- Sponsor
- Genor Biopharma
- Start
- Apr 2019
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of geptanolimab in metastatic colorectal cancer (mCRC), sponsored by Genor Biopharma. Primary endpoints: Adverse Event up to 52 weeks, Dose Limited Toxicity up to 52 weeks and 1 more. Status: unknown.
02
Drugs
geptanolimab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03977090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03977090.